This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F00.0 (G30.0†) — mental and behavioral axis code. Paired code: G30.0 (neurological axis) | Special Copayment Reduction: V800 (severe intractable disease, 5 years) |
| B. Synonyms | Alzheimer disease type 2, presenile dementia (Alzheimer type), primary degenerative dementia of the Alzheimer type (presenile onset), presenile Alzheimer disease |
| C. Adult onset | Adult onset: yes — onset before age 65 by definition; familial early-onset Alzheimer (EOAD) can present even in the 30s to 50s. |
| 1. History | 1906: Alois Alzheimer reported the first case (Auguste D., age 51); described independently as presenile dementia; debate over continuity with senile dementia → single-disease concept established in the 1970s–80s. |
| 2. Causes | Variants in the amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes (familial); APOE ε4 allele; accumulation of amyloid plaques and neurofibrillary tangles. |
| 3. Genetics | Mutations in APP (chromosome 21), PSEN1 (chromosome 14), PSEN2 (chromosome 1); association with Down syndrome (trisomy 21); APOE ε4 as a risk factor. |
| 4. General epidemiology | About 5% of all Alzheimer; one of the most common causes of dementia under age 65; familial cases 0.5–1%. |
| 5. Pathophysiology | Amyloid hypothesis: Aβ production-clearance imbalance → plaque formation → tau phosphorylation → neurofibrillary tangles → synaptic loss → neuronal death. |
| 6. Symptoms | In early-onset EOAD, non-memory cognitive symptoms (language, visuospatial, executive function) are prominent; rapid progression. |
| 7. Signs | Neuropsychological testing (MMSE, MoCA, ADAS-cog); brain MRI (hippocampal atrophy); FDG-PET and amyloid PET; cerebrospinal fluid Aβ42, total tau, and phosphorylated tau. |
| 8. Screening | Genetic counseling and genetic testing when there is a family history; regular follow-up neuropsychological testing in high-risk groups. |
| 9. Diagnosis | NIA-AA 2018 biomarker-based diagnostic framework (A/T/N); confirmation of amyloid by cerebrospinal fluid or PET. |
| 10. Treatment | Cholinesterase inhibitors (donepezil, rivastigmine, galantamine); memantine; lecanemab and donanemab (anti-amyloid monoclonal antibodies); non-pharmacological interventions. |
| 11. Prognosis | Early onset progresses rapidly with early loss of occupational and social function; median survival after diagnosis 8–10 years. |
| 12. Prevention | Management of modifiable risk factors (blood pressure, blood glucose, exercise, education, smoking and alcohol); FINGER multidomain intervention. |
| 13. References | Jack CR et al. Lancet Neurol 2018 and 9 other references |
The history of Alzheimer disease begins in 1906, when the German neuropathologist Alois Alzheimer (1864–1915) performed an autopsy on Auguste Deter, a female patient who developed presenile dementia at age 51, and reported neurofibrillary tangles and amyloid plaques in the cerebral cortex. Alzheimer first presented this case at the 1906 annual meeting of the Society of Southern German Psychiatrists and Natural Scientists, and published it as a scientific paper in 1907. His supervisor Emil Kraepelin named this pathology an independent clinical entity in his 1910 psychiatry textbook, giving it the name "Alzheimer's disease (Alzheimer's Krankheit)."
Initially, Alzheimer disease was regarded as presenile dementia arising before age 65, while onset at 65 or older was classified as simple "senile dementia," and debate continued over whether they were independent diseases. In 1968, Martin Roth and colleagues in the UK systematically demonstrated that the same neuropathological findings were observed in the brains of patients with senile dementia, and in 1976 Katzman published an influential paper arguing that senile dementia and Alzheimer disease are the same disease, establishing the single-disease concept. Accordingly, ICD-10 distinguishes F00.0 (under 65, early onset) and F00.1 (65 or older, late onset) by age of onset but classifies them as the same disease spectrum.
The NINCDS-ADRDA clinical diagnostic criteria published in 1984 by the NIA-AA (National Institute on Aging–Alzheimer's Association) were used as the standard for decades. Subsequently, revised biomarker-based diagnostic criteria were proposed in 2011 and 2018, making a biological definition possible from the preclinical stage (preclinical AD), before clinical symptoms appear. The FDA approval of lecanemab in 2023 marked the introduction of the first disease-modifying treatment targeting amyloid plaques and opened a new chapter in Alzheimer disease treatment.
In ICD-10, dementia due to Alzheimer disease is classified by a dual coding (dagger-asterisk) system. F00.0 is the "*" (asterisk) code for the "†" (dagger) code G30.0, expressing that the underlying neurological disease, Alzheimer disease (G30.0, neurological axis), causes the mental and behavioral symptoms of dementia (F00.0, mental health axis). That is, F00.0 is the code describing the mental and behavioral aspect of the dementia syndrome due to Alzheimer disease, while G30.0 describes the underlying neuropathology (early-onset Alzheimer disease itself). In clinical practice the two codes are used together in principle, and the choice of the principal diagnosis code may differ depending on the perspective of each specialty (neurology vs. psychiatry). In this document, F00.0 is described with a focus on the onset of dementia symptoms and the mental and behavioral aspects, and G30.0 (neuropathology, Alzheimer disease itself) is covered in a separate document.
The causes of F00.0 (dementia in early-onset Alzheimer disease) are broadly divided into hereditary (familial) and sporadic. In early-onset Alzheimer disease (EOAD: onset before age 65), genetic factors account for a much larger share than in late-onset disease.
About 10–15% of all EOAD is autosomal dominant familial Alzheimer disease (FAD) due to a single-gene variant. The main causative genes are APP (amyloid precursor protein, chromosome 21), PSEN1 (presenilin-1, chromosome 14), and PSEN2 (presenilin-2, chromosome 1). Pathogenic variants in these genes cause abnormal cleavage of amyloid precursor protein and increase production of the highly aggregation-prone Aβ42. PSEN1 variants are the most common (about 70–80% of FAD) and tend to have the earliest age of onset (onset in the 30s–50s in some).
In Down syndrome (trisomy 21), a trisomy of chromosome 21, increased APP gene copy number leads to excess Aβ production, so that Alzheimer neuropathology develops in almost all adults with Down syndrome (after about age 40) and about two-thirds progress to clinical dementia. They are formally included in early-onset Alzheimer disease.
APOE ε4 is the strongest risk gene for sporadic Alzheimer disease (especially late onset), but it also increases risk in EOAD. APOE ε4 homozygotes (ε4/ε4) are associated with earlier onset and more rapid cognitive decline than heterozygotes.
About 85–90% of EOAD is sporadic, not explained by a single-gene variant, and arises from the combined action of polygenic risk factors and environmental factors. Modifiable risk factors such as hypertension, diabetes, obesity, smoking, physical inactivity, low education level, hearing loss, and depression contribute in combination.
The genetics of early-onset Alzheimer disease is the most actively studied area of Alzheimer research.
The APP (amyloid precursor protein) gene on chromosome 21 is sequentially cleaved by β-secretase (BACE1) and γ-secretase (presenilin complex) to produce Aβ40 and Aβ42. Pathogenic variants in the APP gene (especially variants within the transmembrane region: V717I, V717F, etc., and the Swedish mutation: K670N/M671L) increase Aβ42 production or increase total Aβ production. APP duplication also causes EOAD, consistent with the model in which an extra APP copy in Down syndrome causes EOAD.
PSEN1, located on chromosome 14, encodes the catalytic subunit of the γ-secretase complex. PSEN1 variants (more than 300 pathogenic variants identified to date) alter the cleavage specificity of γ-secretase and increase the Aβ42/Aβ40 ratio. Age of onset varies from 25 to 65 years depending on the variant, and some variants produce particularly early EOAD with onset in the 30s–40s.
PSEN2 variants, located on chromosome 1, are less common than PSEN1 variants (about 5% of FAD), with somewhat later onset (40–75 years) and lower penetrance. The N141I variant has been reported in a concentrated manner in Volga German families owing to a founder effect.
The APOE ε4 allele (chromosome 19) reduces Aβ clearance and promotes amyloid plaque formation. In ε4/ε4 homozygotes, Alzheimer risk is increased about 15-fold compared with ε3/ε3.
When a pathogenic variant in one of APP, PSEN1, or PSEN2 is identified, it is transmitted to offspring with a 50% probability in an autosomal dominant manner. When a family member has early-onset dementia, specialized genetic counseling and genetic testing are recommended, and sufficient pre-test counseling is essential for predictive genetic testing.
Early-onset Alzheimer disease (onset before age 65, EOAD) accounts for about 5–9% of all Alzheimer disease patients. Worldwide, EOAD patients are estimated at about 3–4 million. Among causes of dementia under age 65, Alzheimer disease is the most common, and together with vascular dementia and frontotemporal dementia it is one of the 3 leading causes.
By age of onset, prevalence is known to be about 54/100,000 at ages 45–64 and about 3.1/100,000 at ages 30–44. Very early onset (before age 40), including familial FAD, is very rare. The difference in incidence by sex is known to be less pronounced in EOAD than in Alzheimer disease overall (female predominance).
In Korea, nationwide epidemiological studies of early-onset dementia in those in their 60s or younger are limited, but according to Central Dementia Center statistics, the proportion of dementia patients under 65 is about 5–7%. Because early onset occurs in the working-age years, it causes social problems qualitatively different from late-life onset, such as job loss, family support problems, and socioeconomic burden.
The amyloid cascade hypothesis is the most widely accepted theory of the pathophysiology of Alzheimer disease. In EOAD in particular, the mechanism by which increased Aβ production due to a genetic defect directly causes amyloid plaque formation has been clearly confirmed.
Unlike the normal processing pathway of APP (non-amyloidogenic pathway), when PSEN1/2 or APP variants are present, the highly aggregation-prone Aβ42 is overproduced during sequential cleavage of APP. Aβ42 aggregates sequentially from monomers to oligomers, protofilaments, fibrils, and plaques. In particular, Aβ oligomers are a toxic form that directly impairs synaptic function and are regarded as the main mediator of neurotoxicity.
Aβ accumulation induces hyperphosphorylation of tau protein. Normal tau is involved in stabilizing microtubules, but hyperphosphorylated tau detaches from microtubules and forms paired helical filaments (PHF) within the cell, which accumulate as neurofibrillary tangles (NFTs). NFTs obstruct intracellular transport and cause neuronal death. The pattern of spread of tau pathology within the brain (Braak stages I–VI) correlates with the severity of clinical symptoms.
Activated microglia and reactive astrocytes gather around amyloid plaques and cause a neuroinflammatory response. That Alzheimer risk genes found by GWAS, such as TREM2, CLU, CR1, and BIN1, are related to microglial function supports a central role of neuroinflammation in pathogenesis.
The combined action of Aβ toxicity and tau pathology causes synaptic loss and damages many neurotransmitter systems, including cholinergic neurons (nucleus basalis of Meynert in the basal forebrain), glutamatergic neurons, and serotonergic neurons. In particular, cholinergic neuron loss is the main mechanism of impaired memory formation and provides the therapeutic rationale for acetylcholinesterase inhibitors.
The clinical symptoms of F00.0 (dementia in early-onset Alzheimer disease) are fundamentally similar to those of F00.1 (late onset), but early onset has several characteristic differences.
Impairment of short-term (episodic) memory is the most common initial symptom, beginning with forgetting recent conversations, appointments, and the location of objects. This is because episodic memory depends on the hippocampus and entorhinal cortex, and Alzheimer neuropathology begins first in these areas.
In EOAD (onset before age 65), non-memory cognitive symptoms tend to be more prominent than in late onset. Language impairment (difficulty finding words, reduced fluency), visuospatial processing abnormalities (getting lost, difficulty drawing, errors in judging distance), executive dysfunction (ability to plan, solve problems, and organize sequences), apraxia (difficulty using tools and dressing), and agnosia (difficulty recognizing people and objects) may appear markedly from the beginning. For this reason, EOAD more often presents as a "non-amnestic phenotype" that begins without memory impairment than late-onset disease.
Depression, anxiety, apathy, social withdrawal, and irritability may appear together with or before cognitive symptoms. In EOAD in particular, declining work performance and abnormal social judgment appear as early symptoms and often lead to job loss.
The diagnostic criteria for dementia include not only cognitive decline but also decline in activities of daily living (ADL). EOAD patients experience marked difficulty in their prior social roles (job, household management, financial management), and after passing through the mild cognitive impairment (MCI) stage, basic ADL (washing, eating, mobility, etc.) gradually decline as well.
Objective signs of Alzheimer dementia consist of neuropsychological testing, neuroimaging, and cerebrospinal fluid and blood biomarkers.
Standardized cognitive tests such as the MMSE (Mini-Mental State Examination), MoCA (Montreal Cognitive Assessment), and ADAS-cog (Alzheimer Disease Assessment Scale-cognitive subscale) are used. A comprehensive neuropsychological battery enables multidomain assessment of memory, language, visuospatial function, executive function, and attention. In EOAD, early decline is identified in the language, visuospatial, and executive function domains in addition to episodic memory.
On MRI (structural MRI), atrophy of the medial temporal lobe (hippocampus, entorhinal cortex, amygdala) is characteristic, and in EOAD atrophy of the parietal and frontal lobes is also prominent. On FDG-PET, reduced glucose metabolism is observed in the posterior cingulate cortex, parieto-temporal cortex, and frontal association areas. Amyloid PET (florbetapir, flutemetamol, florbetaben) directly images Aβ plaques and confirms the biological diagnosis. Tau PET images the distribution of NFTs and is used for staging.
In cerebrospinal fluid, decreased Aβ42 (sequestration in plaques), increased total tau (t-tau) (neuronal injury), and increased phosphorylated tau (p-tau) (NFT formation) are the key markers for the biological diagnosis of Alzheimer disease. A lowered Aβ42/Aβ40 ratio has higher diagnostic accuracy than Aβ42 alone. Recently, blood-based biomarkers (plasma p-tau217, p-tau181, Aβ42/Aβ40) have shown high predictive value and their clinical use is expanding.
Screening for Alzheimer disease in the general population is not currently recommended. However, systematic assessment of high-risk groups may contribute to early diagnosis.
When there is a family history of familial Alzheimer disease, genetic counseling and molecular genetic testing (APP, PSEN1, PSEN2 gene panel) are recommended. In adults with Down syndrome, regular cognitive function assessment (monitoring of changes in adaptive behavior and memory decline) is recommended from age 30. Because people with the APOE ε4 homozygous genotype (ε4/ε4) have a markedly higher Alzheimer risk, they are advised to undergo early evaluation when symptoms appear, along with risk factor management.
In patients complaining of subjective cognitive decline (SCD), especially when cognitive difficulties affect occupational or daily functioning, comprehensive neuropsychological testing and biomarker assessment are performed.
For the diagnosis of Alzheimer dementia, the 2011 and 2018 NIA-AA criteria (A/T/N biomarker framework) are the international standard.
A/T/N framework: A (amyloid) = abnormal amyloid PET or cerebrospinal fluid Aβ42/Aβ40; T (tau) = tau PET or elevated cerebrospinal fluid p-tau; N (neurodegeneration) = FDG-PET, MRI atrophy, elevated cerebrospinal fluid t-tau. Confirmation of A+ is essential for the biological diagnosis of Alzheimer disease.
Clinical diagnostic stages: subjective cognitive decline (A+T±N±) → preclinical Alzheimer (A+, asymptomatic) → mild cognitive impairment due to Alzheimer (A+T+, MCI AD) → Alzheimer dementia (A+T+N+, with functional decline). Because EOAD patients are in the active working-age years, differential diagnosis from other causes (vascular, frontotemporal, Lewy body, metabolic, etc.) is especially important.
For differential diagnosis, basic blood tests (thyroid function, vitamin B12, folate, fasting blood glucose, renal and liver function, complete blood count, syphilis serology, HIV, etc.) and brain MRI are essential.
Treatment of Alzheimer dementia is divided into symptomatic treatment and disease-modifying therapy (DMT).
Donepezil, rivastigmine, and galantamine inhibit acetylcholinesterase and increase acetylcholine concentration in the synapse. In mild-to-moderate Alzheimer dementia they temporarily alleviate the decline in cognitive and daily functioning. Donepezil is also used in severe dementia. Adverse effects: gastrointestinal symptoms (nausea, vomiting, diarrhea), bradycardia.
An uncompetitive NMDA receptor antagonist that reduces glutamate excitotoxicity. In moderate-to-severe Alzheimer dementia it helps maintain cognitive function and relieve behavioral symptoms, and can be combined with cholinesterase inhibitors.
Lecanemab (Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils and received full FDA approval in 2023. In early Alzheimer disease (MCI AD or mild dementia, A+), it slowed clinical decline by 27% at 18 months (CLARITY AD study). It is administered by intravenous infusion every 2 weeks, and amyloid-related imaging abnormalities (ARIA) are the main adverse effect. Donanemab also received FDA approval in 2024 and slowed clinical decline by 35% in early Alzheimer disease (TRAILBLAZER-ALZ 2 study). The risk of ARIA is high in APOE ε4 homozygotes, so careful evaluation is needed when applying it.
Cognitive stimulation training, exercise therapy (especially aerobic exercise), occupational therapy (daily functioning training), music therapy, and non-pharmacological approaches to behavioral problems are recommended. An SSRI may be used when depression or anxiety is present, and a low-dose antipsychotic (quetiapine, etc.) when behavioral problems are severe, but caution regarding adverse effects is needed in elderly dementia patients.
EOAD is characterized by faster disease progression than late onset and a large socioeconomic burden because it occurs during the working years. Median survival after diagnosis is reported at about 8–10 years, but varies widely with age of onset, type of pathogenic variant, and comorbid conditions. PSEN1 variant carriers often show the most rapid course.
EOAD patients lose their jobs at a young age, so financial problems and changes in family relationships are serious. The caregiving burden on spouses and children is large, and because the patients themselves relatively retain awareness of their illness, psychological distress may be great. Depression, suicidal ideation, and anxiety are reported to be more frequent in EOAD than in late onset.
With the introduction of anti-amyloid treatment (lecanemab, donanemab), disease progression in early Alzheimer disease is partly delayed, but at the current stage a cure or long-term halting of progression cannot be expected. Combination strategies such as tau-targeted therapy and synapse-protective therapy are expected to contribute to improved prognosis in the future.
Prevention of Alzheimer dementia centers on management of modifiable risk factors. The 2020 Lancet Commission on dementia estimated that 12 modifiable risk factors (low education level, hypertension, hearing loss, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation) can account for about 40% of all dementia. The FINGER study (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) conducted in Finland showed that a multicomponent intervention of vascular risk factor management, exercise, cognitive training, and nutrition significantly prevents cognitive decline.
Primary prevention is very difficult in familial EOAD. Preclinical-stage treatment trials such as the DIAN-TU (Dominantly Inherited Alzheimer Network Treatment Unit) study are currently underway, and starting anti-amyloid treatment several years before symptom onset is being explored as a prevention strategy.